Founded in 1965 as a local community pharmacy, Carie Boyd Pharmaceuticals now compounds office-use and patient-specific medications for healthcare providers and patients nationwide. Its FDA-registered 503B outsourcing facility and 503A specialty pharmacy are especially known for implantable hormone pellets, with the company having pioneered an automated pellet-compounding process. The facilities follow cGMP and USP standards while developing customized medications for needs that commercial products may not meet.
FDA-Registered 503B Outsourcing Facility
registration
Current Good Manufacturing Practices (cGMP), 21 CFR Parts 210 and 211
compliance_program
United States Pharmacopeia (USP) Compliance
compliance_program